Aug 13, 2020
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
Jun 17, 2020
Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Jun 08, 2020
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
Jun 05, 2020
Ionis Pharmaceuticals to present at upcoming virtual investor conferences
May 28, 2020
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
May 14, 2020
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
May 06, 2020
Ionis reports first quarter 2020 financial results and recent business achievements
May 05, 2020
Akcea Reports Financial Results and Highlights for First Quarter 2020
May 01, 2020
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
Apr 22, 2020
Ionis Pharmaceuticals to hold first quarter 2020 financial results webcast
Apr 20, 2020
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
Feb 27, 2020
Ionis Pharmaceuticals to present at upcoming investor conferences
Feb 26, 2020
Ionis provides fourth quarter and full year 2019 financial results
Jan 22, 2020
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Jan 09, 2020
Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
Jan 07, 2020
Ionis' neurological franchise marks year of achievement
Dec 02, 2019
Ionis Pharmaceuticals to hold technology webcast
Nov 06, 2019
Ionis provides third quarter financial results and improved 2019 guidance
Oct 28, 2019
Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference
Oct 23, 2019
Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences